Información:
Error:
ID
42118
Descripción
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01405573
Link
https://clinicaltrials.gov/show/NCT01405573
Palabras clave
Versiones (2)
- 27/5/16 27/5/16 -
- 10/4/21 10/4/21 - Ahmed Rafee, MD
Titular de derechos de autor
folgt
Subido en
10 de abril de 2021
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Advanced Adult Hepatocellular Carcinoma NCT01405573
Eligibility Advanced Adult Hepatocellular Carcinoma NCT01405573
- StudyEvent: Eligibility
Similar models
Eligibility Advanced Adult Hepatocellular Carcinoma NCT01405573
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
hepatic cell carcinoma
Item
patients with diagnosis of hepatic cell carcinoma (hcc) according to the aasld- easl criteria
boolean
C2239176 (UMLS CUI [1])
age
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
locoregional hcc
Item
advanced stage of disease defined as hcc not eligible for locoregional treatments (ab initio or following progression after such treatments)
boolean
C0027643 (UMLS CUI [1])
child-pugh class b
Item
liver function classified as child-pugh class b
boolean
C3831116 (UMLS CUI [1])
ecog
Item
ecog performance status < or = 2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy of at least 2 months
boolean
C0023671 (UMLS CUI [1])
contraception
Item
adequate contraception for fertile male and female patients
boolean
C0420837 (UMLS CUI [1])
informed consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
sorafenib
Item
prior exposure to sorafenib or antiangiogenesis drugs
boolean
C1516119 (UMLS CUI [1])
C0596087 (UMLS CUI [2])
C0596087 (UMLS CUI [2])
concomitant diseases
Item
concomitant diseases that contraindicate the use of sorafenib
boolean
C0150941 (UMLS CUI [1])
gastro-intestinal bleeding
Item
gastro-intestinal bleeding in the previous 30 days
boolean
C0017181 (UMLS CUI [1])
renal function, hemoglobin
Item
altered renal function(creatinine > 1.5 x uln), or haematological function (platelet count < 60 x 10^9/l, hemoglobin < 9 g/dl)
boolean
C0518015 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232804 (UMLS CUI [2])
active infections
Item
serious active infections (> grade 2 ctcae version 3.0)
boolean
C0009450 (UMLS CUI [1])
congestive heart failure
Item
congestive heart failure, history of congestive heart failure, unstable angina pectoris, myocardial infarct or significant valvular heart disease or uncontrolled heart arrhythmia
boolean
C0018802 (UMLS CUI [1])
patients who are unable or unwilling to participate in the study
Item
patients who are unable or unwilling to participate in the study
boolean
C2348568 (UMLS CUI [1])
pregnant or lactating females
Item
pregnant or lactating females
boolean
C0549206 (UMLS CUI [1])
C2828358 (UMLS CUI [2])
C2828358 (UMLS CUI [2])
hepatic encephalopathy
Item
hepatic encephalopathy of any grade
boolean
C0019151 (UMLS CUI [1])
Sin comentarios